期刊文献+

怡脉颗粒对动脉粥样硬化家兔Hs-CRP、MMP-9的影响

Effects of Yimai Granule on the Atherosclerotic Rabbits In Hs-CRP,MMP-9
下载PDF
导出
摘要 目的利用高脂喂饲诱发动脉粥样硬化模型,探讨中药怡脉颗粒对家兔动脉粥样硬化的干预作用及其机制。方法32只日本雄性大耳白兔随机分为四组(空白对照组、模型对照组、血脂康组、怡脉颗粒组),每组8只,其中怡脉颗粒组和血脂康组造模的同时给药,前两组以等量蒸馏水灌胃10周后测定各组空腹血清高敏C反应蛋白(Hs-CRP)和基质金属蛋白酶-9(MMP-9)含量。结果模型对照组Hs-CRP及MMP-9较空白对照组明显升高,怡脉颗粒组和血脂康组Hs-CRP及MMP-9均明显低于模型对照组,怡脉颗粒组MMP-9明显低于血脂康组。结论怡脉颗粒对动脉粥样硬化有明显的预防和治疗作用,降低Hs-CRP及MMP-9可能是其作用机制之一。 Objective: The model of atheroselerosis was established by feeding the cholesterol contained fodder to study the effect of Yimai granule on rabbits with atheroselerosis. Methods: Thirty - two Japanese white rabbits with large ears were divided randomly into four groups, each group had eight: control group, model group, xuezhikang group and Yimai granule group. The drugs were administrated along with the replication of the model xuezhikang group and Yimai granule group in the first two groups intra gastric administration by equal quantity of distilled water. After ten weeks, the concentrations of High sensitive Creaetiveprotein(Hs- CRP) and Matrix Metalloproteinase(MMP-9) in each group were measured. Results: Compared with the control group, the level of Hs - CRP and MMP - 9 in model group increased. Compared with the model group, the concentrations of Hs - CRP and MMP - 9 in xuezhikang group and Yimai granule group obviously decreased. Compared with the xuezhikang group, the level of MMP - 9 decreased in the Yimai granule group. Conclusion: The Yimai granule was a potential drug for treatment and prevention of atheroselerosis. The effect of Yimai granule depends most probably on the decrease of Hs - CRP and MMP - 9.
出处 《中国中医急症》 2008年第10期1429-1430,共2页 Journal of Emergency in Traditional Chinese Medicine
基金 安徽省教育厅青年教师科研资助项目(No2004jq169)
关键词 动脉粥样硬化 怡脉颗粒 高敏C反应蛋白 基质金属蛋白酶-9 Atherosclerosis Yimai granule Hs - CRP MMP - 9 Rabbit
  • 相关文献

参考文献5

二级参考文献42

  • 1孔丽君.高敏CRP与心血管事件的预测[J].实用中西医结合临床,2004,4(5):84-85. 被引量:12
  • 2Lauer-Fields JL, Tuzinski KA, Shimokawa KI, et al.Hydrolysis of triple-helical collagen peptide models by matrix meta;oproteinases[J]. J Biol Chem, 2000,275:13282-13290.
  • 3Brew K, Dinakarpandian D, Nagase H. Tissue inhibitor of metalloproteinases: evolution, structure and function[J]. Biochem Biophys Acta, 2000, 1477: 267-283.
  • 4Galis ZS,Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques[J]. J Clin Invest, 1994,94:2493-2503.
  • 5Lauer-Fields JL, Tuzinski KA, Shimokawa KI, et al.Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases[J]. J Biol Chem, 2000,275:13282-13290.
  • 6Nomoto K, Oguchi S, Watanabe I, et al. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular cell adhesion molecule-1 [J]. J Cardiol, 2003,42: 201-206.
  • 7Hisashi K, Hisao I, Hideo Y, et al. Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes[J]. JACC,1998,32: 368-372.
  • 8Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome [J]. Am Heart J, 2001,141:211-217.
  • 9Etoh T, Joffs C, Descharnps AM, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs [J]. Am J Physiol Heart Circ Physiol, 2001,281: H987-H994.
  • 10Podesser BK, Siwik DA, Ebeli FR, et al. Et(a)-receptor blockade prevents matrix metalloproteinase activition late postmyocardial infarction in the rat[J]. Am J Physiol Heart Circ Physiol, 2001,280: H984-H991.

共引文献153

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部